Compare · BDX vs HTFL
BDX vs HTFL
Side-by-side comparison of Becton Dickinson and Company (BDX) and Heartflow Inc. (HTFL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and HTFL operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $52.78B, about 11.9x HTFL ($4.43B).
- BDX has been more active in the news (9 items in the past 4 weeks vs 2 for HTFL).
- BDX has more recent analyst coverage (25 ratings vs 9 for HTFL).
- Company
- Becton Dickinson and Company
- Heartflow Inc.
- Price
- -
- -
- Market cap
- $52.78B
- $4.43B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 9
- 2
- Recent ratings
- 25
- 9
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Latest BDX
- BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026
- BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide
- BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results
- BD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in Canaan
- BD Appoints Ferass Abuzaina as Worldwide President of Surgery
- BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience
- EVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)
- BD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in Sandy
- Arthur Hu to Join BD as Chief Information and Digital Officer
- BD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at Fairview
Latest HTFL
- SEC Form 4 filed by Heartflow Inc.
- Chief Medical Officer Rogers Campbell exercised 13,179 shares at a strike of $7.94 and sold $987,052 worth of shares (19,682 units at $50.15) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 79,956 units (SEC Form 4)
- Chief Financial Officer Verghese Vikram sold $1,230,742 worth of Common Stock. (24,345 units at $50.55) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 155,183 units (SEC Form 4)
- Chief Financial Officer Verghese Vikram sold $1,751,611 worth of Common Stock. (34,975 units at $50.08) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 179,528 units (SEC Form 4)
- Chief Executive Officer Farquhar John C.M. sold $1,819,605 worth of shares (38,900 units at $46.78) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 321,914 units (SEC Form 4)
- Chief Financial Officer Verghese Vikram sold $332,212 worth of Common Stock. (6,640 units at $50.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 214,503 units (SEC Form 4)
- UBS resumed coverage on Heartflow with a new price target
- Chief Financial Officer Verghese Vikram sold $1,665,796 worth of Common Stock. (33,416 units at $49.85) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 221,143 units (SEC Form 4)
- Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half
- Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference